{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:31:10Z","timestamp":1780565470122,"version":"3.54.1"},"reference-count":70,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jaip.2022.09.020","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T13:23:29Z","timestamp":1663939409000},"page":"3075-3086","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Review of Adverse Reactions to Biologics Used in Allergy-Immunology Practice"],"prefix":"10.1016","volume":"10","author":[{"given":"Timothy G.","family":"Chow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Oppenheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam R.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2022.09.020_bib1","first-page":"24","article-title":"Defining the difference: what makes biologics unique","volume":"1","author":"Morrow","year":"2004","journal-title":"Biotechnol Healthc"},{"key":"10.1016\/j.jaip.2022.09.020_bib2","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1398-9995.2006.01058.x","article-title":"Adverse side-effects to biological agents","volume":"61","author":"Pichler","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.09.020_bib3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.iac.2017.01.012","article-title":"Adverse reactions to biologic therapy","volume":"37","author":"Patel","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2022.09.020_bib4","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2022.09.020_bib5","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.mcna.2010.03.001","article-title":"The complex clinical picture of side effects to biologicals","volume":"94","author":"Hausmann","year":"2010","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.jaip.2022.09.020_bib6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s12016-016-8556-5","article-title":"Diagnoses and management of drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: reactions to taxanes and monoclonal antibodies","volume":"54","author":"Bonamichi-Santos","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2022.09.020_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaci.2018.02.018","article-title":"Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes","volume":"142","author":"Isabwe","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.09.020_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/all.14984","article-title":"Hypersensitivity reactions to biologicals: an EAACI position paper","volume":"77","author":"Bavbek","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.09.020_bib10","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jaip.2020.08.006","article-title":"Practical guidance for the evaluation and management of drug hypersensitivity: specific drugs","volume":"8","author":"Broyles","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.09.020_bib9","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaip.2016.12.001","article-title":"Current knowledge and management of hypersensitivity reactions to monoclonal antibodies","volume":"5","author":"Picard","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.09.020_bib11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.anai.2010.10.008","article-title":"The safety and interpretability of skin tests with omalizumab","volume":"105","author":"Lieberman","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.09.020_bib12","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.jaip.2019.06.028","article-title":"Fixed drug eruption to biologics and role of lesional patch testing","volume":"7","author":"Li","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.09.020_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.765747","article-title":"How to prevent and mitigate hypersensitivity reactions to biologicals induced by anti-drug antibodies?","volume":"12","author":"Vultaggio","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2022.09.020_bib14","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose","volume":"358","author":"Chung","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.09.020_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78497-7","article-title":"The role of IgE specific for galactose-\u03b1-1,3-galactose in predicting cetuximab induced hypersensitivity reaction: a systematic review and a diagnostic meta-analysis","volume":"10","author":"Lungulescu","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaip.2022.09.020_bib16","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jaip.2018.07.031","article-title":"A\u00a0large single-hospital experience using drug provocation testing and rapid drug desensitization in hypersensitivity to antineoplastic and biological agents","volume":"7","author":"Madrigal-Burgaleta","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.09.020_bib17","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/all.12620","article-title":"Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization","volume":"70","author":"Alvarez-Cuesta","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.09.020_bib18","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaip.2020.11.021","article-title":"Delabeling patients from chemotherapy and biologics allergy: Implementing drug provocation testing","volume":"9","author":"Vazquez-Revuelta","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.09.020_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12817","article-title":"Injection site reactions with the use of biological agents","volume":"32","author":"Thomaidou","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaip.2022.09.020_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.572863","article-title":"Rituximab hypersensitivity: from clinical presentation to management","volume":"11","author":"Fouda","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaip.2022.09.020_bib21","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1016\/j.jaip.2021.06.024","article-title":"One-dilution rapid desensitization protocol to chemotherapeutic and biological agents: a five-year experience","volume":"9","author":"Sala-Cunill","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.09.020_bib22","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.jaip.2020.11.066","article-title":"Successful administration of omalizumab by desensitization protocol following systemic reactions in 12 patients","volume":"9","author":"Bernaola","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.09.020_bib24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3949\/ccjm.71.3.251","article-title":"Omalizumab: where does it fit into current asthma management?","volume":"71","author":"Rebase","year":"2004","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.jaip.2022.09.020_bib25","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaci.2016.03.030","article-title":"Anaphylactic reactions associated with omalizumab administration: analysis of a case-control study","volume":"138","author":"Lieberman","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.09.020_bib26","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jaci.2007.09.022","article-title":"Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma","volume":"120","author":"Limb","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.09.020_bib27","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jaci.2007.09.032","article-title":"American Academy of Allergy, Asthma & Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis","volume":"120","author":"Cox","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.09.020_bib28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaci.2011.04.010","article-title":"American Academy of Allergy, Asthma & Immunology\/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report","volume":"128","author":"Cox","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.09.020_bib29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.rmed.2017.07.013","article-title":"Long-term \u201creal-life\u201d safety of omalizumab in patients with severe uncontrolled asthma: a nine-year study","volume":"130","author":"Di Bona","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2022.09.020_bib30","first-page":"A359","article-title":"Clinical data do not suggest a causal relationship between omalizumab therapy and cancer","volume":"2","author":"Fernandez","year":"2005","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.jaip.2022.09.020_bib31","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.jaci.2012.01.033","article-title":"Omalizumab and the risk of malignancy: results from a pooled analysis","volume":"129","author":"Busse","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.09.020_bib32","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jaci.2016.07.038","article-title":"Cardiovascular and cerebrovascular events among patients receiving omalizumab: results from EXCELS, a prospective cohort study in moderate to severe asthma","volume":"139","author":"Iribarren","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.09.020_bib33","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaip.2019.09.037","article-title":"Estimation of health and economic benefits of clinic versus home administration of omalizumab and mepolizumab","volume":"8","author":"Shaker","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.09.020_bib35","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2022.09.020_bib36","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaip.2022.09.020_bib37","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/02770903.2019.1630641","article-title":"Usability of mepolizumab single-use prefilled autoinjector for patient self-administration","volume":"57","author":"Bernstein","year":"2020","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.jaip.2022.09.020_bib38","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/02770903.2019.1604745","article-title":"Usability of mepolizumab single-use prefilled syringe for patient self-administration","volume":"57","author":"Bel","year":"2020","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.jaip.2022.09.020_bib39","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"HES mepolizumab study group. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.09.020_bib40","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1164\/rccm.200206-525OC","article-title":"Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study","volume":"167","author":"Kips","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2022.09.020_bib41","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2022.09.020_bib42","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.jaip.2017.08.024","article-title":"Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma","volume":"5","author":"Murphy","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.09.020_bib43","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.09.020_bib44","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an anti-interleukin 5 receptor \u03b1 monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study","volume":"2","author":"Castro","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2022.09.020_bib45","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2022.09.020_bib46","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2022.09.020_bib47","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","article-title":"BORA study investigators. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial","volume":"7","author":"Busse","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2022.09.020_bib48","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.09.020_bib49","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12931-019-1065-3","article-title":"Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials","volume":"20","author":"Xiong","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2022.09.020_bib50","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"SOLO 1 and SOLO 2 investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.09.020_bib51","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jaci.2017.04.015","article-title":"Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: a meta-analysis of randomized clinical trials","volume":"140","author":"Han","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.09.020_bib52","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2022.09.020_bib53","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jaip.2021.12.006","article-title":"Respiratory infections and anti-infective medication use from phase 3 dupilumab respiratory studies","volume":"10","author":"Geng","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.09.020_bib54","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13134","article-title":"Treatment of refractory conjunctivitis associated to dupilumab with topical pimecrolimus applied to the eyelid skin","volume":"32","author":"Sernicola","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaip.2022.09.020_bib55","article-title":"Topical treatment of dupilumab-associated refractory conjunctivitis and keratitis","volume":"25","author":"Di Staso","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.jaip.2022.09.020_bib56","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2147\/OPTH.S336978","article-title":"Clinical characteristics and treatment for dupilumab-related ocular complications in atopic dermatitis patients","volume":"16","author":"Tauqeer","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jaip.2022.09.020_bib57","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa1402895","article-title":"Effects of an anti-TSLP antibody on allergen-induced asthmatic responses","volume":"370","author":"Gauvreau","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.09.020_bib58","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.09.020_bib59","doi-asserted-by":"crossref","unstructured":"Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, et\u00a0al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med 2017;377:936-946 [Erratum: N Engl J Med 2019;380:2082].","DOI":"10.1056\/NEJMoa1704064"},{"key":"10.1016\/j.jaip.2022.09.020_bib60","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jaip.2016.06.022","article-title":"Reactions to rituximab in an outpatient infusion center: a 5-year review","volume":"5","author":"Levin","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.09.020_bib61","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/acr.23781","article-title":"Long-term safety of rituximab in rheumatoid arthritis: analysis from the SUNSTONE registry","volume":"71","author":"Winthrop","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jaip.2022.09.020_bib62","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/rheumatology\/kex446","article-title":"Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection","volume":"57","author":"Henry","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaip.2022.09.020_bib63","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s10067-017-3848-6","article-title":"Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies","volume":"36","author":"Einarsson","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaip.2022.09.020_bib64","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1002\/art.40937","article-title":"Predicting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases","volume":"71","author":"Md Yusof","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaip.2022.09.020_bib65","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11926-021-01037-3","article-title":"Long-term safety of rituximab (risks of viral and opportunistic infections)","volume":"23","author":"Varley","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jaip.2022.09.020_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.671503","article-title":"Rituximab-associated hypogammaglobulinemia in autoimmune disease","volume":"12","author":"Tieu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2022.09.020_bib67","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaip.2022.09.020_bib68","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.20.01086","article-title":"Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD","volume":"39","author":"Watkins","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaip.2022.09.020_bib69","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2022.09.020_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.151955","article-title":"Long-term abatacept treatment for 48 weeks in patients with primary Sj\u00f6gren\u2019s syndrome: the open-label extension phase of the ASAP-III trial","volume":"53","author":"de Wolff","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaip.2022.09.020_bib71","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-020-02399-2","article-title":"Risk of opportunistic infections in patients with rheumatoid arthritis initiating abatacept: cumulative clinical trial data","volume":"23","author":"Simon","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaip.2022.09.020_bib72","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaci.2021.04.039","article-title":"Therapeutic options for CTLA-4 insufficiency","volume":"149","author":"Egg","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822009564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822009564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:37:24Z","timestamp":1761975444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219822009564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":70,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2213219822009564"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2022.09.020","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Review of Adverse Reactions to Biologics Used in Allergy-Immunology Practice","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2022.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}